Today, Indian Institute of Technology, Kanpur achieved historic milestone by signing a Memorandum of Agreement (MoA) with a leading pharmaceutical company Laurus Labs. This collaboration is centered around licensing of gene therapy assets that have emerged from path-breaking research conducted by Prof Jayandharan Rao and his team.

Under this partnership, Laurus Labs Limited will collaborate with IIT Kanpur to develop novel drugs based on gene therapy assets, focusing on treating challenging disorders such as retinal degeneration, hemophilia, and muscular dystrophy. The aim is to provide affordable treatment options not only in India but also in emerging markets.

In addition to developing novel drugs, Laurus Labs will establish a state of art manufacturing facility located at IIT Kanpur's research park, Techno Park. This facility will serve as a hub for collaborative efforts between Laurus Labs and IIT Kanpur for pre-clinical and clinical trials. The presence of Laurus Labs within Techno Park will foster a stronger partnership between IIT Kanpur and Laurus Labs team.

With the setting up of Gangwal School of Medical Sciences and Technology at IIT Kanpur and centers like The Mehta Family Center for Engineering in Medicine, we are committed to transformative research in affordable healthcare, including novel drug discovery, medical diagnostics and therapeutics, medical devices, and implants.

Establishing this partnership showcases IIT Kanpur's dedication to fostering strong collaboration between academia and industry while highlighting the industry's trust in the institute's research initiatives to promote self reliance (Atmanirbhar Bharat).

This collaboration marks a significant moment in IIT Kanpur's journey of innovation and its pursuit of advancing healthcare solutions for the betterment of society.